Wall Street analyst estimates for Kairos Pharma, Ltd. (KAPA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd.
Valuation Ratios
| Price / Book | 1.32 |
| EV / EBITDA | -0.53 |
| Dividend Yield | 0.00% |
Price
| Price | $1.81 |
| Market Cap | $6M |
| Exchange | AMEX |
| Country | US |
Explore sector: Healthcare · Biotechnology
More sections of KAPA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks